Genome & Company (KOSDAQ:314130)
South Korea · Delayed Price · Currency is KRW 2,575.00
+15.00 (0.59%)
Last updated: Aug 29, 2025, 9:07 AM KST
Genome & Company Revenue
Genome & Company had revenue of 6.35B KRW in the quarter ending March 31, 2025, with 49.11% growth. This brings the company's revenue in the last twelve months to 29.84B, up 86.35% year-over-year. In the year 2024, Genome & Company had annual revenue of 27.74B with 94.07% growth.
Revenue (ttm)
29.84B
Revenue Growth
+86.35%
P/S Ratio
3.31
Revenue / Employee
245.08M
Employees
98
Market Cap
79.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 27.74B | 13.45B | 94.07% |
| Dec 31, 2023 | 14.30B | 211.39M | 1.50% |
| Dec 31, 2022 | 14.08B | 13.63B | 3,021.27% |
| Dec 31, 2021 | 451.25M | 300.66M | 199.67% |
| Dec 31, 2020 | 150.58M | 104.75M | 228.54% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Electronics | 308.59T |
| SK hynix | 77.21T |
| LG Energy Solution | 25.16T |
| Samsung Biologics | 5,031.69B |
| Hyundai Motor Company | 182.25T |
| Hanwha Aerospace | 19.25T |
| HD Hyundai Heavy Industries | 15.58T |
| Kia Corporation | 111.04T |